Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 5/20 | 0.64 |
| ▸ | CRBN | Q96SW2 | 10/20 | 0.62 |
| ▸ | CA2 | P00918 | 2/20 | 0.62 |
| ▸ | DDB1 | Q16531 | 8/20 | 0.61 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.60 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 3/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19475853 | 1.00 | STAT3 (0.64) | STAT3CRBNCA2DDB1DYRK2 | |
| SCHEMBL19508773 | 1.00 | STAT3 (0.64) | STAT3CRBNCA2DDB1DYRK2 | |
| SCHEMBL19475728 | 1.00 | STAT3 (0.64) | STAT3CRBNCA2DDB1DYRK2 | |
| SCHEMBL19475706 | 1.00 | STAT3 (0.64) | STAT3CRBNCA2DDB1DYRK2 | |
| SCHEMBL30000661 | 0.97 | CRBN (0.63) | STAT3CRBNCA2DDB1DYRK2 | |
| SCHEMBL29877119 | 0.96 | CRBN (0.61) | STAT3CRBNCA2DDB1DYRK2 | |
| SCHEMBL24418634 | 0.95 | CRBN (0.65) | STAT3CRBNCA2DDB1DYRK2 | |
| SCHEMBL30000878 | 0.92 | CRBN (0.66) | STAT3CRBNCA2DDB1DYRK2 | |
| SCHEMBL24745682 | 0.92 | CRBN (0.66) | STAT3CRBNCA2DDB1DYRK2 | |
| SCHEMBL29880821 | 0.92 | CRBN (0.71) | STAT3CRBNCA2DDB1DYRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220265834-A1 | BCL-2 PROTEIN INHIBITORS | RECURIUM IP HOLDINGS, LLC | 2022-08-25 | — | — | US | disclosed |
| EP-3972966-A1 | BCL-2 PROTEIN INHIBITORS | Recurium IP Holdings, LLC (US) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220265834-A1 | BCL-2 PROTEIN INHIBITORS | BCL2, BCL2L1, BCL2L2 | STAT3 479/4885CRBN 317/4885CA2 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.